http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010311559-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60f67cf07e3fdc9c7d98b1c36039ec12 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2010-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b40569c7c79680bf9ecee2955a2f936 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_019dbe210362c8497af90ac59392319b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d549b9a65c30df0204aa91791d65251c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ff19b92f2facd2be08cbd575759806d |
| publicationDate | 2016-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2010311559-B2 |
| titleOfInvention | Dosage regimen for administering a CD19xCD3 bispecific antibody |
| abstract | The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19xCD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19x CD3 bispecific antibody to a human patient having a B :T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use of a CD19x CD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well. |
| priorityDate | 2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.